JNJ is taking heat for its unwillingness to allow cheap generics for its HIV drugs in poor countries: http://www.ft.com/intl/cms/s/0/d6ca3afa-2cbf-11e1-b485-00144feabdc0.html#axzz1hNrqY9l8 Right or wrong, what JNJ doesn’t need these days is more bad publicity, so I’m surprised by the company’s deportment on this matter.